Jubilant Pharmova's Q3 FY 2025-26 Quarterly Results
- 07 Feb 2026
Result Summary
- Jubilant Pharmova Ltd reported a 8.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 17.0%.
- Its expenses for the quarter were up by 12.9% QoQ and 19.5% YoY.
- The net profit decreased 53.5% QoQ and decreased 44.6% YoY.
- The earnings per share (EPS) of Jubilant Pharmova Ltd stood at 3.52 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 2143.00 | 1976.20 | 1830.90 | 8.4% | 17.0% |
Total Expenses | 2009.80 | 1780.00 | 1681.20 | 12.9% | 19.5% |
Profit Before Tax | 93.50 | 190.40 | 130.80 | -50.9% | -28.5% |
Tax | 37.60 | 70.40 | 29.80 | -46.6% | 26.2% |
Profit After Tax | 55.80 | 119.90 | 100.70 | -53.5% | -44.6% |
Earnings Per Share | 3.52 | 7.57 | 6.36 | -53.5% | -44.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Jubilant Pharmova Ltd is a prominent player in the pharmaceutical industry, known for its focus on innovation and manufacturing excellence. The company engages in manufacturing and marketing a wide range of pharmaceutical and life sciences products. Jubilant Pharmova is involved in various segments including pharmaceuticals, contract research and manufacturing services, and proprietary products. The company operates globally, serving a diverse clientele with its high-quality products. Recent strategic initiatives have focused on expanding its product portfolio and enhancing its manufacturing capabilities to meet increasing demand.
Revenue
In the third quarter of fiscal year 2026 (Q3FY26), Jubilant Pharmova Ltd reported a total income of ₹2143.00 crores. This represents an increase of 8.4% from the previous quarter (Q2FY26), where the total income was ₹1976.20 crores. On a year-over-year basis, the total income saw a growth of 17.0%, compared to ₹1830.90 crores in Q3FY25. The upward trend in revenue indicates robust growth over both short-term and annual comparisons. The company's ability to achieve such growth can be attributed to its strategic focus on expanding market reach and product offerings.
Profitability
Jubilant Pharmova Ltd experienced notable shifts in profitability during Q3FY26. The company recorded a profit before tax (PBT) of ₹93.50 crores, which is a decline of 50.9% quarter-over-quarter and 28.5% year-over-year. The tax expense for the quarter stood at ₹37.60 crores, reflecting a decrease of 46.6% QoQ, yet marking a 26.2% increase YoY. Consequently, the profit after tax (PAT) was reported at ₹55.80 crores, down by 53.5% from the previous quarter and 44.6% from the same period last year. Earnings per share (EPS) followed a similar trend, declining to ₹3.52 from ₹7.57 in Q2FY26 and ₹6.36 in Q3FY25, reflecting a decrease of 53.5% QoQ and 44.7% YoY.
Operating Metrics
Total expenses for Jubilant Pharmova Ltd in Q3FY26 amounted to ₹2009.80 crores, marking an increase of 12.9% from the preceding quarter and 19.5% from the same quarter in the previous year. This rise in expenses could be indicative of increased operational activities or cost pressures. Despite the increase in total income, the higher rate of expense growth relative to revenue contributed to the observed decline in profitability metrics. The company’s financial performance depicts a scenario where revenue growth is accompanied by rising costs, impacting overall profitability.